|vTv to Host Key Opinion Leader Event to Discuss the Current State of Clinical Development in Alzheimer’s Disease|
The event will feature two speakers, each with extensive experience in the clinical development in Alzheimer’s:
In addition to the presentations,
A live webcast of the event will be available on the Investor page of vTv’s website at www.vtvtherapeutics.com. The archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of vTv Therapeutics’ website for 90 days following the event.
vTv discovered and developed azeliragon using its proprietary drug discovery platform TTP Translational Technology®. A broad range of human pathologic and experimental biologic investigation suggests that RAGE activation contributes to the pathogenesis of Alzheimer’s disease. Sustained Amyloid-β interactions with RAGE at the blood-brain barrier (BBB) and in neuronal and microglial cells, play potentially major roles in amyloid plaque formation, neuroinflammation and chronic neural dysfunction – all hallmarks of Alzheimer’s disease. Azeliragon, also known as TTP488, is a novel orally active small-molecule antagonist of RAGE.
STEADFAST, two identical randomized, double-blind, placebo-controlled
Phase 3 trials, is investigating the safety and efficacy of azeliragon
as a potential treatment to slow the decline in cognition and functional
activities for patients with mild Alzheimer’s disease. The 18-month
trial targeted enrollment of 800 patients (400 each for Part A and B).
Part A enrolled patients in
This release contains forward-looking statements, which involve risks
and uncertainties. These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
“anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,”
“plan,” “potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and, in each case, their negative or other various or comparable
terminology. All statements other than statements of historical facts
contained in this release, including statements regarding the timing of
our clinical trials, our strategy, future operations, future financial
position, future revenue, projected costs, prospects, plans, objectives
of management and expected market growth are forward-looking statements.
These statements involve known and unknown risks, uncertainties and
other important factors that may cause our actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Important factors that could cause our results to vary from
expectations include those described under the heading “Risk Factors” in
our Annual Report on Form 10-K and our other filings with the